Evidence mapPaperPMID 41315136Full record

ArticleBiogerontology2025

Circadian rhythm of amyloid-β in the olfactory bulb and cerebellum of wild-type and APPxPS1 knock-in mice indicates a loss of rhythmicity in regions more vulnerable to amyloid pathology.

Valeria A Buzinova, Carrie E Johnson, Savannah M Turton, Sarah E Barth, Samantha Padgett, M Tyler Maisel, Katharina Kohler, Haleigh R Whitlock, Adam D Bachstetter, Sridhar Sunderam and 3 more

Abstract read
In one paragraph

Article in Biogerontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Valeria A BuzinovaDepartment of Molecular and Cellular Biochemistry, University of Kentucky, 432 Health Sciences Research Building, Lexington, KY, USA.
Carrie E JohnsonDepartment of Molecular and Cellular Biochemistry, University of Kentucky, 432 Health Sciences Research Building, Lexington, KY, USA.
Savannah M TurtonThe Sanders-Brown Center On Aging, University of Kentucky, 789 S. Limestone Street, 541 Lee Todd Jr. Building, Lexington, KY, USA.
Sarah E BarthThe Sanders-Brown Center On Aging, University of Kentucky, 789 S. Limestone Street, 541 Lee Todd Jr. Building, Lexington, KY, USA.
Samantha PadgettThe Sanders-Brown Center On Aging, University of Kentucky, 789 S. Limestone Street, 541 Lee Todd Jr. Building, Lexington, KY, USA.
M Tyler MaiselDepartment of Neuroscience, University of Kentucky, 432 Health Sciences Research Building, Lexington, KY, USA.
Katharina KohlerThe Sanders-Brown Center On Aging, University of Kentucky, 789 S. Limestone Street, 541 Lee Todd Jr. Building, Lexington, KY, USA.
Haleigh R WhitlockDepartment of Neuroscience, University of Kentucky, 432 Health Sciences Research Building, Lexington, KY, USA.
Adam D BachstetterDepartment of Neuroscience, University of Kentucky, 432 Health Sciences Research Building, Lexington, KY, USA.
Sridhar SunderamDepartment of Biomedical Engineering, University of Kentucky, 432 Health Sciences Research Building, Lexington, KY, USA.
Bruce F O'HaraDepartment of Biology, University of Kentucky, 432 Health Sciences Research Building, Lexington, KY, USA.
Marilyn J DuncanDepartment of Neuroscience, University of Kentucky, 432 Health Sciences Research Building, Lexington, KY, USA. mjdunc0@uky.edu.
M Paul MurphyDepartment of Molecular and Cellular Biochemistry, University of Kentucky, 432 Health Sciences Research Building, Lexington, KY, USA. mpmurp3@uky.edu.

Funding

Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)T32AG078110 · UNIVERSITY OF KENTUCKY · 2025 to 2025
$441k
NIA NIH HHS R01 AG068215NIA NIH HHS T32 AG078110NIH HHS AG068215T32 AG078110
6 · The paper itself

Abstract

Amyloid-β (Aβ) plaques are one of the primary biomarkers of Alzheimer's Disease (AD). Other publications have reported various mechanisms regarding the clearance of Aβ, and recent studies have also investigated the relationship between daily rhythms of Aβ and AD. The intent of this study was to determine if the circadian rhythm of Aβ differed between a region that was more vulnerable to AD-related pathology (the olfactory bulbs; OB) compared to a region that is less vulnerable (the cerebellum; CER). We chose to utilize an APPxPS1 knock-in (KI) mouse strain as this strain expresses amyloid precursor protein (APP) and Aβ under control of its normal promoter as opposed to AD transgenic models that overexpress APP and, as a consequence, Aβ. Mice (N = 128, equally divided between male and female, wild type and KI) were acclimated to a 12:12 light cycle for two weeks, and tissue was collected over a 24-h period in constant darkness. Using a unique immunoassay designed to measure human or rodent Aβ side-by-side, we confirmed a robust circadian Aβ rhythm in the mouse brain and that the OB contains more overall Aβ accumulation than the CER. The circadian Aβ rhythm was not present in the OB of the KI as compared to the WT mice. In contrast, the Aβ rhythm in the CER did not differ between genotypes. These results suggest that the loss of Aβ rhythm in disease-affected brain regions may be associated with the development of AD pathology and could have important implications for therapy.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorCerebellumCircadian RhythmOlfactory BulbPresenilin-1AnimalsDisease Models, AnimalFemaleGene Knock-In TechniquesMaleMiceMice, Inbred C57BLMice, TransgenicAmyloid beta-PeptidesAmyloid beta-Protein PrecursorPresenilin-1AgingAlzheimer’s diseaseAmyloid-β precursor proteinDaily rhythmImmunoassays

Identifiers

PMID41315136
PMCPMC13072434

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.